Lara PN - Search Results

1

Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer.

Chen Y, Tu MJ, Han F, Liu Z, Batra N, Lara PN, Chen HW, Bi H, Yu AM. Chen Y, et al. Among authors: lara pn. Acta Pharm Sin B. 2023 Oct;13(10):4273-4290. doi: 10.1016/j.apsb.2023.07.011. Epub 2023 Jul 15. Acta Pharm Sin B. 2023. PMID: 37799388 Free PMC article.

2

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.

Jian C, Tu MJ, Ho PY, Duan Z, Zhang Q, Qiu JX, DeVere White RW, Wun T, Lara PN, Lam KS, Yu AX, Yu AM. Jian C, et al. Among authors: lara pn. Oncotarget. 2017 May 9;8(19):30742-30755. doi: 10.18632/oncotarget.16372. Oncotarget. 2017. PMID: 28415566 Free PMC article.

3

Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy.

Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, Hu Z, Wun T, Lara PN, DeVere White RW, Chen HW, Yu AM. Ho PY, et al. Among authors: lara pn. J Pharmacol Exp Ther. 2018 Jun;365(3):494-506. doi: 10.1124/jpet.118.247775. Epub 2018 Mar 30. J Pharmacol Exp Ther. 2018. PMID: 29602831 Free PMC article.

4

RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype.

Cai D, Wang J, Gao B, Li J, Wu F, Zou JX, Xu J, Jiang Y, Zou H, Huang Z, Borowsky AD, Bold RJ, Lara PN, Li JJ, Chen X, Lam KS, To KF, Kung HJ, Fiehn O, Zhao R, Evans RM, Chen HW. Cai D, et al. Among authors: lara pn. Nat Commun. 2019 Oct 11;10(1):4621. doi: 10.1038/s41467-019-12529-3. Nat Commun. 2019. PMID: 31604910 Free PMC article.

5

In vivo fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy.

Li PC, Tu MJ, Ho PY, Batra N, Tran MML, Qiu JX, Wun T, Lara PN, Hu X, Yu AX, Yu AM. Li PC, et al. Among authors: lara pn. Theranostics. 2021 Mar 4;11(10):4858-4871. doi: 10.7150/thno.56596. eCollection 2021. Theranostics. 2021. PMID: 33754032 Free PMC article.

6

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.

McCoach CE, Yu A, Gandara DR, Riess JW, Vang DP, Li T, Lara PN, Gubens M, Lara F, Mack PC, Beckett LA, Kelly K. McCoach CE, et al. Among authors: lara pn, lara f. JCO Precis Oncol. 2021 Jan 14;1:PO.20.00279. doi: 10.1200/PO.20.00279. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34036220 Free PMC article.

7

ATR Inhibition in Advanced Urothelial Carcinoma.

Leibrandt RC, Tu MJ, Yu AM, Lara PN, Parikh M. Leibrandt RC, et al. Among authors: lara pn. Clin Genitourin Cancer. 2023 Apr;21(2):203-207. doi: 10.1016/j.clgc.2022.10.016. Epub 2022 Nov 4. Clin Genitourin Cancer. 2023. PMID: 36604210 Free PMC article. Review.

8

Neoadjuvant therapy for non-small cell lung cancer.

Gandara DR, Lara PN Jr, Goldberg Z, Roberts P, Lau DH. Gandara DR, et al. Among authors: lara pn jr. Anticancer Drugs. 2001 Feb;12 Suppl 1:S5-9. Anticancer Drugs. 2001. PMID: 11340902 Review.

9

Non-small-cell lung cancer progression after first-line chemotherapy.

Lara PN Jr, Lau DH, Gandara DR. Lara PN Jr, et al. Curr Treat Options Oncol. 2002 Feb;3(1):53-8. doi: 10.1007/s11864-002-0041-0. Curr Treat Options Oncol. 2002. PMID: 12057087 Review.

10

Docetaxel in non-small cell lung cancer: a review.

Davies AM, Lara PN Jr, Mack PC, Gandara DR. Davies AM, et al. Among authors: lara pn jr. Expert Opin Pharmacother. 2003 Apr;4(4):553-65. doi: 10.1517/14656566.4.4.553. Expert Opin Pharmacother. 2003. PMID: 12667118 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

279 results

Search Page